**Name and institution**

**PD Dr Oleg Timofeev**
Philipps-Universität Marburg
Institut für Molekulare Onkologie
Zentrum für Tumor- und Immunbiologie (ZTI)
Hans-Meerwein-Str. 3, 35043 Marburg
Tel.:+49(0)06421-28-26288
Fax:+49(0)6421-28-24292
E-Mail: timofeev@staff.uni-marburg.de
Web: https://www.uni-marburg.de/en/fb20/departments/zti/imo/staff/timofeev
ORCID 0000-0002-3114-6403

| | |
|---|---|
| Position | Research scientist, Group leader |
| Date of Birth | 06.09.1969, male |

**Academic career**

| | |
|---|---|
| 6/2016 | Habilitation at the Philipps-University of Marburg for Molecular Oncology |
| 8/2010- | Senior Post-doc, Group leader at the Institute of Molecular Oncology, Philipps-University of Marburg |
| 11/2008 – 06/2010 | Project coordinator, R&D department, Alkor-Bio Group, St.Petersburg, Russia |
| 08/2005 – 11/2008 | Post-doc at the Cell Cycle Control and Carcinogenesis group, German Cancer Research Centre, Heidelberg |
| 03/2004 – 02/2005 | Guest Scientist, Cell Cycle regulation and Tumorigenesis group, Institute of Molecular and Cell Biology, Singapore |
| 06/2003 – 12/2003 | Guest Scientist, Basic Research Laboratory, National Cancer Institute, NIH, Bethesda, USA |
| 02/2002 – 08/2002 | Practical student (grantee), Institute of Molecular Biology, Center for Cancer Research and Cancer Therapy, University of Essen |
| 10/2000 – 11/2002 | Scientific assistant, Department of Molecular Mecanisms of Cell Differentiation, Institute of Cytology, Russian Academy of Sciences, St.-Petersburg, Russia |

**Academic degrees**

| | |
|---|---|
| 10/2016 | Privat-Dozent, Philipps-University of Marburg, Habilitation Thesis “Stress-induced pathways in tumor suppression” |
| 03/2005 | Kandidat Nauk (Candidate of Science, Russian equivalent of PhD), Institute of Cytology of Russian Academy of Science (St. Petersburg, Russia), Thesis: “The role of p38 MAPK and Wip1 phosphatase in tumor suppression and tumorigenesis” |

**University education**

| | |
|---|---|
| 06/2000 – 10/2002 | MSc, St. Petersburg State University (St. Petersburg, Russia) |
| 05/2000 | BSc, St. Petersburg State University |
| 5/1992 – 5/2000 | Study of Biology and Informatics at the St. Petersburg State University and St. Petersburg Industrial College |

**Publications (last 5 years)**

1. Klimovich B, Meyer L, Merle N, Neumann M, König A, Ananikidis N, Keber C, Elmshäuser S, Timofeev O*, Stiewe T "Partial p53 reactivation is sufficient to induce cancer regression" (2022) **J of Experimental & Clinical Cancer Research** *co-senior author (IF 9.95)
2. Klimovich B, Merle N, Neumann M, Elmshäuser S, Nist A, Mernberger M, Kazdal D, Stenzinger A, Timofeev O*, Stiewe T. (2021) p53 Partial Loss-of-Function Mutations Sensitize to Chemotherapy. **Oncogene** doi: 10.1038/s41388-021-02141-5 *co- senior author (IF 8.64)
3. Timofeev O & Stiewe T "Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy" (2021) **Cancers** 13(10):2422 (IF 6.126)
4. Timofeev O "Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments" (2021) **Front Oncol** 11:740578 (IF 4.84)
5. Klimovich B, Stiewe T, Timofeev O. (2020) Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo. **Cell Cycle** 19(1):109-123. (IF 4.53)
6. Timofeev O, Koch L, Niederau C, Tscherne A, Schneikert J, Klimovich M, Elmshauser S, Zeitlinger M, Mernberger M, Nist A, Osterburg C, Dotsch V, German Mouse Clinic C, Hrabe de Angelis M, and Stiewe T. (2020). Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging. Cancer Res 80: 5231-5244. (Highlighted by: Horikawa I. (2020). Balancing and Differentiating p53 Activities toward Longevity and No Cancer? **Cancer Res** 80: 5164-5165. (IF 12.70)
7. Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, Wanzel M, Stiewe T. „mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability" (2020) **Nat Commun** 11(1):4684 (IF 14.919)
8. Klimovich B, Mutlu S, Schneikert J, Elmshäuser S, Klimovich M, Nist A, Mernberger M, Timofeev O*, Stiewe T*. (2019) Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy. **Proc Natl Acad Sci U S A**. 2019 116(44): 22288-22293. (IF 11.21) * co- senior author
9. Timofeev O, Klimovich B, Schneikert J, Wanzel M, Pavlakis E, Noll J, Mutlu S, Elmshauser S, Nist A, Mernberger M, Lamp B, Wenig U, Brobeil A, Gattenlohner S, Kohler K, and Stiewe T. (2019). Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. EMBO J 38: e102096. (Highlighted by: Manfredi JJ. (2019). p53 defies convention again: a p53 mutant that has lost tumor suppression but still can kill. **EMBO J** 38: e103322.) (IF 11.60)
10. Timofeev O & Stiewe T "p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding." (2017) **Mol Cell Oncol** 4: e1288678 (IF 1.48)